Intravenous Immunoglobulin Market – Synopsis
Intravenous Immunoglobulin (IVIg), a compound comprising of immune proteins (globulins) is administered into the bloodstream to treat patients with the inefficient or damaged immune systems. IVIg suffices the required antibodies by the human body to fight out the immune deficiency, and the consequent infectious attacks. Immunodeficiency Disorder could be a hereditary issue (Primary disorders), or caused due to the exposure to infections, mainly through bodily fluids, along with the cancer drugs and chemotherapy, aging is one of the key risk factor too that could put someone at greater risk of a damaged immune system.
Market Research Future (MRFR) has recently published a study report giving out the complete market forecast up to 2023. In its analysis, MRFR asserts that the global Intravenous Immunoglobulin Market Growth growing further will reach USD 8337.2 Million by 2023, registering 5.9% CAGR during 2017 to 2023.
Leveraging to the modern age, people have adopted the heady & unhealthy lifestyles which mirror the prevalence of damaged immune system. Factors such as immense of stress, lack of good quality sleep, inadequate & improper diet and sedentary lifestyle are fuelling the prevalence of Immunodeficiency Disorder. And, the augmented prevalence is predominantly driving the market growth.
Acknowledging the kind of the growth the market perceives currently;
The augmenting demand for alternate immunoglobulin replacement therapies, increasing R&D funding, rapidly developing healthcare infrastructure and increasing healthcare expenditures are major driving forces for the market growth. Technological advancements transpired in the medical science, are fostering the market growth exponentially, bringing up novel treatment procedures, & medications in the field of IVIg.
- Abeona Therapeutics
- BDI Pharma
- China Biologic Products
- Biotest AG
- Grifols Inc
- CSL Behring
Intravenous Immunoglobulin Market – Competitive Analysis
The global IVIg market is fiercely competitive with the presence of several large and small players operating in the market. These market players acquire promising companies to expand in the fast-growing markets, focusing on improving their market performance. The market structure is dynamic due to the acquisition of local manufactures by the multinational companies. Strategies like product innovations and technologies are creating strong investment opportunities for the market players.
Intravenous Immunoglobulin Market – Segments
- Global Intravenous Immunoglobulin (IVIg) Market has been segmented on the basis of type which comprise IgA (sub segments- IgA1 and IgA2), IgD, IgE, IgG,.
- On the basis of application it segmented into CIDP (Progressive, Recurrent, Monophasic), Hypogammaglobulinemia (sub segments- AGM1, AGM2, AGM3, AGM4, AGM5, AGM6), Multifocal Motor Neuropathy, Immunodeficiency diseases (sub segments- X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), severe combined immunodeficiency), Primary Humoral Immunodeficiency (Subsegments- B cell (antibody) deficiencies, T cell deficiencies, Combination B and T cell deficiencies, Defective phagocytes, Complement deficiencies, Unknown (idiopathic)), Myasthenia Gravis (Sub segments- generalized myasthenia gravis, ocular myasthenia gravis, Congenital myasthenia gravis, Transient neonatal myasthenia gravis), Guillain-Barre syndrome (Sub segments- Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), Miller Fisher syndrome (MFS), Acute motor axonal neuropathy (AMAN)and acute motor-sensory axonal neuropathy (AMSAN)), Kawasaki disease, ITP (Sub segments- acute and chronic), and others.
Intravenous Immunoglobulin Market – Geographical Analysis
Globally, North America is the leading market for IVIg, accounting for the largest revenue pocket, followed by the Europe & Asia Pacific markets, respectively. The US market backed by the high expenditure on healthcare is the largest contributor to the regional market growth. Moreover, increasing prevalence of immunodeficiency disorder and rising demand for treatment measures provide impetus to the market growth.
On the other hand, Europe, the world’s second-largest market for IVIg, is fostered by the high per capita income and robust healthcare penetration in the region. The strong market growth in the countries like Germany & France drives the regional market growth, large scale. Attributing to the increasing investment in healthcare and rising number of patients with immune system diseases, the market is projected to register a phenomenal CAGR during the forecast period.
Asia Pacific market for the Intravenous Immunoglobulin is expected to perceive an exponential growth. Owing to the huge population and the burgeoning medical treatment market, India & China drive the regional market growth. Vietnam, Thailand, and Malaysia among the other South East Asian countries are projected to contribute significantly to the regional market growth. With the growing Medical Tourism markets in India & Malaysia the APAC region will register a significant CAGR during the review period.